Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Hemab ApS to treat bleeding disorders; and Amylyx Pharmaceuticals, Inc. to develop a novel long-acting GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.